The Biochemistry of A1c Formation and Measurement

Hemoglobin A1c is one of the most widely used biomarkers in diabetes care. It offers a convenient snapshot of average blood glucose over the preceding 2–3 months, guiding both diagnosis and treatment adjustments. Yet, clinicians and patients alike are increasingly aware that A1c readings do not always tell the whole story. Genetic factors can significantly alter A1c values independently of actual glycemic control, leading to misinterpretation, misclassification, and missed opportunities for optimal management. Understanding these genetic influences is essential for accurate diabetes assessment and personalized care.

A1c is formed through a non‑enzymatic process called glycation, in which glucose molecules attach to the N‑terminal valine of the beta‑chain of hemoglobin. The rate of this reaction depends on the prevailing glucose concentration over the life span of the red blood cell (RBC). Because RBCs typically circulate for ~120 days, the proportion of glycated hemoglobin reflects average glucose over that interval. This relationship assumes a constant rate of glucose exposure, stable RBC survival, and uniform glycation kinetics—assumptions that are frequently violated by genetic variation.

Modern A1c assays fall into two broad categories: methods based on charge separation, such as high‑performance liquid chromatography (HPLC) and capillary electrophoresis, and methods based on structural recognition, such as immunoassays and enzymatic assays. Each method interacts differently with hemoglobin variants and chemically modified hemoglobins. For example, HPLC separates hemoglobin species by charge, so a variant with a different net charge (e.g., HbS or HbC) may elute at a different time, potentially causing the instrument to under‑ or overestimate the A1c fraction. Immunoassays rely on antibody binding to the glycated N‑terminus of the beta‑chain; variants at or near that site can alter binding affinity and produce inaccurate results. Enzymatic assays, while less susceptible to some interferences, may still be impacted by certain variants. These assay‑specific susceptibilities are a key reason why genetic variability must be considered when interpreting A1c.

Genetic Factors Influencing A1c Levels

Hemoglobin Variants

More than 1,000 hemoglobin variants have been described, many of which can interfere with A1c measurement. The most clinically relevant include:

  • Hemoglobin S (HbS) – The variant responsible for sickle cell disease. Heterozygotes (HbAS, sickle cell trait) often have no anemia but exhibit slightly lower A1c values by some methods due to reduced RBC survival and altered chromatographic properties. In homozygous sickle cell disease (HbSS), RBC survival is dramatically reduced to 10–30 days, rendering A1c virtually uninterpretable.
  • Hemoglobin C (HbC) – Common in West African populations. HbC trait (HbAC) can cause falsely low A1c readings with certain HPLC systems and immunoassays. Homozygotes (HbCC) have mild hemolytic anemia, further complicating interpretation. The crystal formation in HbCC cells accelerates RBC destruction.
  • Hemoglobin E (HbE) – Frequent in Southeast Asia. HbE trait (HbAE) shows minimal effect on most assays, but HbEE homozygotes have microcytic anemia and reduced A1c. HbE is one of the most common variants globally, affecting millions.
  • Hemoglobin D (HbD), HbG, HbO‑Arab, and others – Less common but can cause assay interference, especially on ion‑exchange HPLC. HbD-Punjab, for instance, co-elutes with HbA in some systems and may produce falsely elevated or decreased results.
  • α‑Thalassemia and β‑Thalassemia traits – These conditions reduce hemoglobin production and cause microcytosis. Because the total hemoglobin concentration is lower and RBC turnover may be increased, A1c can be falsely decreased relative to the true average glucose. In β‑thalassemia major, transfusion dependence further complicates interpretation.

The impact of hemoglobin variants is not merely a laboratory curiosity. A large study published in Diabetes Care found that among African‑American individuals with sickle cell trait, a clinically significant proportion had A1c values that were 0.3–0.5% lower than what would be predicted from fasting glucose and oral glucose tolerance tests.[1] Without awareness, a patient with prediabetes could be misclassified as normal, or a diabetic patient’s glucose control could appear better than it truly is. Similarly, a study in JAMA demonstrated that HbC trait carriers had A1c levels approximately 0.3% lower than non-carriers at equivalent glucose concentrations.[2]

Red Blood Cell Turnover and Lifespan

Because A1c reflects the glycation of hemoglobin over the lifespan of RBCs, any condition that alters RBC survival will directly affect the measured A1c. Genetic disorders that shorten RBC lifespan—and thus reduce the time available for glycation—lead to artefactually low A1c levels. Conversely, conditions that prolong RBC survival (rare) can elevate A1c.

  • Sickle cell disease (HbSS) – Characterized by chronic hemolysis; RBC survival is reduced to 10–30 days. A1c is profoundly low and does not correlate with glucose levels. Alternate measures such as fructosamine or glycated albumin are required.
  • Hereditary spherocytosis, elliptocytosis – Genetic defects in the RBC membrane cause premature destruction by the spleen, often resulting in low A1c. Splenectomy can paradoxically increase A1c by prolonging RBC survival.
  • Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency – An X‑linked disorder common in Africa, the Mediterranean, and Asia. Hemolytic episodes triggered by oxidant stress shorten RBC lifespan and lower A1c between crises. The effect is intermittent and unpredictable.
  • Pyruvate kinase deficiency – A rare autosomal recessive condition causing chronic hemolytic anemia; A1c is unreliable. Newer enzyme replacement therapies are emerging, but monitoring remains challenging.
  • Hereditary stomatocytosis – A group of rare membrane disorders causing cation leakage and hemolysis, with similar effects on A1c reliability.

Even in the absence of overt hemolytic disease, subtle genetic variations in RBC lifespan exist. Genome‑wide association studies (GWAS) have identified loci near the HK1 and G6PC2 genes that are associated with A1c independently of fasting glucose.[3] These findings suggest that inherited differences in erythrocyte biology can shift A1c by 0.1–0.3% in otherwise healthy individuals—enough to influence the diagnosis of prediabetes or diabetes at the population level. The HK1 locus, in particular, has been replicated across multiple cohorts and appears to affect RBC glucose metabolism and survival.

Genetic Polymorphisms in Glycation Pathways

Not everyone glycates hemoglobin at the same rate for a given glucose concentration. Genetic factors controlling the permeability of the RBC membrane to glucose, intracellular glucose metabolism, and the activity of deglycation enzymes (e.g., fructosamine‑3‑kinase) can all influence the degree of hemoglobin glycation. GWAS have identified a locus near the FN3K gene that associates with A1c independent of glucose.[4] Individuals with certain variants may have a lower or higher A1c for the same time‑averaged glucose, meaning A1c is not a perfectly standardized surrogate for glycemia across all people. The FN3K gene encodes fructosamine-3-kinase, an enzyme that reverses glycation; polymorphisms that alter its activity can shift the equilibrium between glycated and non-glycated hemoglobin. Additionally, variants in SLC2A1 (encoding GLUT1, the erythrocyte glucose transporter) may affect how much glucose enters the RBC, further modulating glycation rates.

Ethnic and Racial Disparities in A1c Interpretation

The prevalence of hemoglobin variants and RBC disorders varies widely among ethnic groups. For example, sickle cell trait is present in approximately 8% of African‑Americans, and HbC trait in about 2%. α‑Thalassemia trait occurs in 30–40% of individuals from Southeast Asia and parts of Africa. HbE trait is found in up to 30% of people in Cambodia, Laos, and Thailand. These demographic patterns mean that reliance on A1c without consideration of genetic background can disproportionately affect certain populations, potentially exacerbating health inequities. A study in Diabetes Care reported that among Asian Americans, HbE variants led to A1c underestimation by 0.2–0.4% in a significant subset.[5]

Several studies have documented that, for the same measured fasting or post‑load glucose, African‑American individuals tend to have higher A1c values than white individuals. This difference persists after adjusting for socioeconomic and metabolic factors, pointing to a genetic component. While higher A1c may reflect true differences in glycemia, it could also arise from altered glycation kinetics or RBC survival. The clinical consequence is that African‑Americans are more likely to be diagnosed with diabetes at a slightly lower average glucose, or are more likely to be classified as having poor glycemic control. Clinicians must be aware of these racial‑ethnic nuances and, when possible, corroborate A1c with other data such as self‑monitored blood glucose or continuous glucose monitoring (CGM). The American Diabetes Association (ADA) now recommends considering genetic variants when interpreting A1c in diverse populations.

Clinical Challenges and Practical Solutions

Given the complex interplay of genetics and A1c, clinicians need a systematic approach to avoid misdiagnosis and mismanagement. The consequences of ignoring genetic interference are significant: patients may be denied therapy due to falsely low A1c, or subjected to unnecessary treatment intensification due to falsely high values. Hypoglycemia risk also increases when treatment decisions are based on unreliable A1c data.

When to Suspect a Genetic Interference

  • Unexplained discrepancy between A1c and self‑monitored blood glucose levels or CGM data (e.g., A1c < 6% despite average glucose > 180 mg/dL).
  • Very low A1c (<4.5%) without evidence of hypoglycemia or in the context of well‑controlled diabetes.
  • A1c that does not change despite clear changes in glucose control (e.g., after initiating insulin).
  • Patient of African, Mediterranean, Southeast Asian, or Middle Eastern descent (higher prevalence of variants).
  • Family history of hemoglobinopathy, hemolytic anemia, or thalassemia.
  • Unexplained anemia, jaundice, or splenomegaly.
  • Abnormal RBC indices (low MCV, MCH) without iron deficiency.

Steps for Accurate Assessment

  1. Consider the assay method. Laboratories often use HPLC or capillary electrophoresis; these reports usually flag the presence of a possible variant. Clinicians should review the chromatogram comment or ask the lab about known interferences. Some HPLC systems automatically flag abnormal peaks.
  2. Order a hemoglobinopathy screen if a variant is suspected (e.g., Hb electrophoresis, isoelectric focusing, or DNA testing). This is especially important in patients with unexplained anemia or microcytosis.
  3. Use an alternative glycemic marker. Fructosamine (total serum protein glycation) or glycated albumin can be measured. Fructosamine reflects glycemic control over 2–3 weeks, while glycated albumin (primarily used in research) has a similar window. CGM provides the most comprehensive real‑time picture and is increasingly accessible.
  4. Interpret A1c cautiously in at‑risk populations. The American Diabetes Association (ADA) recommends that when A1c cannot be interpreted reliably, the diagnosis of diabetes should be made using fasting plasma glucose, 2‑hour OGTT glucose, or CGM metrics.[6]
  5. Adjust treatment targets. In patients with hemolytic anemia, A1c is not meaningful for monitoring, so goals should be based on glucose measurements, not A1c. For patients with hemoglobin variants, consider a baseline glycation study using CGM to establish individual A1c-glucose relationships.
  6. Educate patients. Explain that their A1c may not be a reliable marker and why alternative monitoring is needed. This reduces confusion and improves adherence to monitoring regimens.

Future Directions: Genetics and Personalized Diabetes Care

Advances in genomic medicine are paving the way for more personalized interpretation of A1c. Polygenic risk scores that incorporate variants affecting RBC biology, glycation efficiency, and hemoglobin structure could eventually allow individual‑level calibration of A1c to true average glucose. Researchers are also developing “glycated hemoglobin‑adjusted” formulas that use genetic and demographic data to generate a corrected A1c. Until such tools enter routine clinical practice, awareness and a low threshold for alternative testing remain the best protections against genetic‑based misinterpretation.

In addition, large‑scale studies using CGM as a reference are clarifying the magnitude of A1c‑glucose discordance across genetic subgroups. These data will help refine diagnostic thresholds and monitoring targets for diverse populations. Pharmacogenomic approaches may also emerge, where knowledge of a patient’s RBC biology influences drug choice (e.g., drugs that affect RBC turnover). The integration of artificial intelligence with electronic health records could flag patients at risk for A1c interference based on ancestry, lab values, and medication history, prompting clinicians to consider alternative testing proactively.

Conclusion

Genetic factors exert a meaningful and often underappreciated influence on A1c levels. Hemoglobin variants, altered RBC lifespan, and inherited differences in glycation kinetics can all cause A1c to misrepresent true glycemic status. For clinicians, the key takeaway is to remain vigilant: when A1c and clinical picture do not align, investigate possible genetic interference. Using alternative markers like fructosamine or CGM can restore diagnostic accuracy and ensure that patients receive appropriate, personalized care. As our understanding of the genetics of A1c matures, diabetes management will become increasingly precise, improving outcomes for all individuals regardless of their genetic background.

By integrating genetic awareness into routine practice, we can transform A1c from a one‑size‑fits‑all metric into a more nuanced tool—one that acknowledges the biological diversity of the patients we serve. The ultimate goal is to ensure that every patient receives accurate diagnosis and monitoring, free from the hidden distortions of genetic variation.